Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-23-013821
Filing Date
2023-04-28
Accepted
2023-04-28 08:38:09
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFA14A fy2022proxynotice.htm DEFA14A 4172
2 fy2022proxynotice001.jpg GRAPHIC 99174
3 fy2022proxynotice002.jpg GRAPHIC 144405
4 fy2022proxynotice003.jpg GRAPHIC 85260
  Complete submission text file 0001628280-23-013821.txt   458197
Mailing Address 21 ERIE ST. CAMBRIDGE MA 02139
Business Address 21 ERIE ST. CAMBRIDGE MA 02139 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41536 | Film No.: 23860572
SIC: 2836 Biological Products, (No Diagnostic Substances)